Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
3.13 (1y: +161%)
Market Cap 2.88 B P/E(ttm) 26.10
Enterprise Value 8.95 B P/B
RAD- NYSE (USA)
Rite Aid Corporation
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$3.13
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry		 vs
history
Cash to Debt 0.021
RAD's Cash to Debt is ranked lower than
59% of the 452 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.58 vs. RAD: 0.021 )
RAD' s 10-Year Cash to Debt Range
Min: 0.02   Max: 0.1
Current: 0.02
0.02
0.1
Equity to Asset -0.347
RAD's Equity to Asset is ranked lower than
70% of the 452 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.46 vs. RAD: -0.347 )
RAD' s 10-Year Equity to Asset Range
Min: -0.35   Max: 0.29
Current: -0.35
-0.35
0.29
Interest Coverage 1.3
RAD's Interest Coverage is ranked lower than
51% of the 452 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 11.30 vs. RAD: 1.3 )
RAD' s 10-Year Interest Coverage Range
Min: 0   Max: 3
Current: 1.3
0
3
F-Score: 6
Z-Score: 2.3
M-Score: -3.14
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry		 vs
history
Operating margin (%) 2.50
RAD's Operating margin (%) is ranked higher than
62% of the 452 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.20 vs. RAD: 2.50 )
RAD' s 10-Year Operating margin (%) Range
Min: -8.8   Max: 5.1
Current: 2.5
-8.8
5.1
Net-margin (%) 0.5
RAD's Net-margin (%) is ranked higher than
52% of the 452 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.10 vs. RAD: 0.5 )
RAD' s 10-Year Net-margin (%) Range
Min: -11.1   Max: 7.4
Current: 0.5
-11.1
7.4
ROA (%) 1.7
RAD's ROA (%) is ranked higher than
55% of the 452 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.70 vs. RAD: 1.7 )
RAD' s 10-Year ROA (%) Range
Min: -35   Max: 18.2
Current: 1.7
-35
18.2
ROC (Joel Greenblatt) (%) 17.80
RAD's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 452 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 17.60 vs. RAD: 17.80 )
RAD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -26   Max: 17.8
Current: 17.8
-26
17.8
Revenue Growth (%) -1
RAD's Revenue Growth (%) is ranked lower than
62% of the 452 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.00 vs. RAD: -1 )
RAD' s 10-Year Revenue Growth (%) Range
Min: -14.2   Max: 5.2
Current: -1
-14.2
5.2
EBITDA Growth (%) 17.2
RAD's EBITDA Growth (%) is ranked higher than
96% of the 452 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.00 vs. RAD: 17.2 )
RAD' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 17.2
Current: 17.2
0
17.2
ยป RAD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

RAD Guru Trades in Q2 2012

Bruce Kovner 3,000,000 sh (+200%)
Jim Simons 4,191,248 sh (+120.11%)
Tom Russo 3,500 sh (unchged)
Steven Cohen Sold Out
» More
Q3 2012

RAD Guru Trades in Q3 2012

Joel Greenblatt 56,798 sh (New)
Ray Dalio 613,900 sh (New)
Tom Russo 3,500 sh (unchged)
Bruce Kovner Sold Out
Jim Simons 2,483,590 sh (-40.74%)
» More
Q4 2012

RAD Guru Trades in Q4 2012

Steven Cohen 87,700 sh (New)
Joel Greenblatt 926,161 sh (+1530.62%)
Jim Simons 6,084,437 sh (+144.99%)
Tom Russo 3,500 sh (unchged)
Ray Dalio 256,000 sh (-58.3%)
» More
Q1 2013

RAD Guru Trades in Q1 2013

Larry Robbins 3,000,000 sh (New)
Steven Cohen 3,451,044 sh (+3835.06%)
Ray Dalio 1,034,700 sh (+304.18%)
Joel Greenblatt 2,291,579 sh (+147.43%)
Tom Russo 3,500 sh (unchged)
Jim Simons 2,070,700 sh (-65.97%)
» More
» Details

Insider Trades

Latest Guru Trades with RAD

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-03-31 Add 147.43%0.13%$1.29 - $1.94 $ 3.1492%2291579
Ray Dalio 2013-03-31 Add 304.18%0.01%$1.29 - $1.94 $ 3.1492%1034700
Joel Greenblatt 2012-12-31 Add 1530.62%0.07%$0.97 - $1.44 $ 3.14183%926161
Ray Dalio 2012-12-31 Reduce -58.3%0.01%$0.97 - $1.44 $ 3.14183%256000
Ray Dalio 2012-09-30 New Buy0.01%$1.12 - $1.45 $ 3.14151%613900
Joel Greenblatt 2012-09-30 New Buy$1.12 - $1.45 $ 3.14151%56798
Richard Perry 2012-03-31 Sold Out 1.1%$1.25 - $2.05 $ 3.14112%0
Joel Greenblatt 2011-09-30 Sold Out 0.0057%$0.9862 - $1.35 $ 3.14173%0
George Soros 2011-09-30 Sold Out 0.0002%$0.9862 - $1.35 $ 3.14173%0
Richard Perry 2011-06-30 Add 56.24%0.2%$1.01 - $1.28 $ 3.14183%14190000
Joel Greenblatt 2011-06-30 Reduce -55.54%0.01%$1.01 - $1.28 $ 3.14183%31175
George Soros 2011-06-30 Reduce -72.05%$1.01 - $1.28 $ 3.14183%10900
George Soros 2011-03-31 New Buy$0.8832 - $1.41 $ 3.14175%39000
Richard Perry 2010-12-31 Add 28.24%0.04%$0.8895 - $0.97 $ 3.14238%9082000
Joel Greenblatt 2010-12-31 New Buy0.02%$0.8895 - $0.97 $ 3.14238%72297
Richard Perry 2010-09-30 New Buy0.1%$0.8699 - $1.1 $ 3.14227%7082000
George Soros 2010-09-30 Sold Out 0.01%$0.8699 - $1.1 $ 3.14227%0
Mario Gabelli 2010-06-30 Sold Out $1 - $1.49 $ 3.14151%0
George Soros 2010-06-30 Reduce -27.9%$1 - $1.49 $ 3.14151%175500
Premium More recent guru trades are included for Premium Members only!!
ยป Financial Charts

Peter Lynch Chart

Ratios

vs
industry		 vs
history
P/E(ttm) 26.40
RAD's P/E(ttm) is ranked higher than
51% of the 366 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 17.00 vs. RAD: 26.40 )
RAD' s 10-Year P/E(ttm) Range
Min: 1.86   Max: 328.5
Current: 26.4
1.86
328.5
P/S 0.10
RAD's P/S is ranked higher than
89% of the 426 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.40 vs. RAD: 0.10 )
RAD' s 10-Year P/S Range
Min: 0.01   Max: 0.24
Current: 0.1
0.01
0.24
PFCF 6.80
RAD's PFCF is ranked higher than
85% of the 318 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.91 vs. RAD: 6.80 )
RAD' s 10-Year PFCF Range
Min: 1.88   Max: 659
Current: 6.8
1.88
659
EV-to-EBIT 14.3
RAD's EV-to-EBIT is ranked higher than
59% of the 376 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 11.76 vs. RAD: 14.3 )
RAD' s 10-Year EV-to-EBIT Range
Min: 11.8   Max: 2606.9
Current: 14.3
11.8
2606.9
PEG 2.6
RAD's PEG is ranked higher than
64% of the 179 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.74 vs. RAD: 2.6 )
RAD' s 10-Year PEG Range
Min: 2.55   Max: 5.02
Current: 2.6
2.55
5.02
Shiller P/E 21.5
RAD's Shiller P/E is ranked lower than
100% of the Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: vs. RAD: 21.5 )
RAD' s 10-Year Shiller P/E Range
Min: 4.41   Max: 329.5
Current: 21.5
4.41
329.5

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 1.3
RAD's Price/Net Current Asset Value is ranked higher than
92% of the 356 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.00 vs. RAD: 1.3 )
RAD' s 10-Year Price/Net Current Asset Value Range
Min: 0.1   Max: 1.9
Current: 1.3
0.1
1.9
Price/Median PS Value 1.4
RAD's Price/Median PS Value is ranked higher than
52% of the 389 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.10 vs. RAD: 1.4 )
RAD' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 2.4
Current: 1.4
0.1
2.4
Price/Peter Lynch Fair Value 5.1
RAD's Price/Peter Lynch Fair Value is ranked lower than
54% of the 100 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.60 vs. RAD: 5.1 )
RAD' s 10-Year Price/Peter Lynch Fair Value Range
Min: 2.6   Max: 2.6
Current: 5.1
Earnings Yield (Greenblatt) 7.00
RAD's Earnings Yield (Greenblatt) is ranked higher than
66% of the 452 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.20 vs. RAD: 7.00 )
RAD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 8.5
Current: 7
0.2
8.5
Forward Rate of Return (Yacktman) -1.23
RAD's Forward Rate of Return (Yacktman) is ranked lower than
63% of the 452 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.00 vs. RAD: -1.23 )
RAD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -83.8   Max: 28.4
Current: -1.23
-83.8
28.4

Business Description

Rite Aid Corporation was incorporated in 1968 and is a Delaware Corporation. It operates its drugstores in 31 states across the country and in the District of Columbia. As of March 3, 2012, It operated 4,667 stores. In its stores, it sells prescription drugs and a wide assortment of other merchandise, which it calls 'front end' products. ront end products include over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, beverages, convenience foods, greeting cards, seasonal merchandise and numerous other everyday and convenience products, as well as photo processing. The Company attempts to distinguish its stores from other national chain drugstores, in part, through its wellness + loyalty program, private brands and its strategic alliance with GNC, a leading retailer of vitamin and mineral supplements. The retail drugstore industry is highly competitive. The Company competes with, among others, retail drugstore chains, independently owned drugstores, supermarkets, mass merchandisers, discount stores, dollar stores and mail order pharmacies. The Company's business is subject to federal, state, and local government laws, regulations and administrative practices. The Company must comply with numerous provisions regulating health and safety, equal employment opportunity, minimum wage and licensing for the sale of drugs, alcoholic beverages, tobacco and other products.
Company Website
SEC Reports
Industry: Pharmaceutical Retailers
Compare:SHDMF, APNHF, GNC, JCOUF, PMC
Traded in other countries:RTA.Germany
ยป More Articles for RAD

Headlines

Articles On GuruFocus.com
Walgreen Co. (WAG) Dividend Stock Analysis Apr 05 2013 
Walgreen Co. (WAG) Dividend Stock Analysis Oct 11 2012 
Walgreen (WAG) Dividend Stock Analysis 2012 Sep 21 2012 
Walgreen Co. (WAG) Dividend Stock Analysis Apr 11 2012 
Walgreen Co. (WAG) Dividend Stock Analysis Sep 30 2011 
Walgreen (WAG) Dividend Stock Analysis 2011 Sep 23 2011 
comment on RAD Jul 23 2011 
FPA Crescent's Steven Romick comments on CVS Caremark May 01 2011 
CVS Caremark Part II - Financials & Valuation May 04 2011 
CVS Caremark Part I - Industry and Business Analysis Apr 18 2011 

More From Our Partners
Will Rite Aid Beat Earnings Est. Again? - Analyst Blog Jun 17 2013 - ZACKS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK